Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Genome-wide association study of response to methylphenidate in 187 children with attention-deficit/hyperactivity disorder.

Mick E, Neale B, Middleton FA, McGough JJ, Faraone SV.

Am J Med Genet B Neuropsychiatr Genet. 2008 Dec 5;147B(8):1412-8. doi: 10.1002/ajmg.b.30865.

PMID:
18821564
2.

Genome-wide association study of blood pressure response to methylphenidate treatment of attention-deficit/hyperactivity disorder.

Mick E, McGough JJ, Middleton FA, Neale B, Faraone SV.

Prog Neuropsychopharmacol Biol Psychiatry. 2011 Mar 30;35(2):466-72. doi: 10.1016/j.pnpbp.2010.11.037. Epub 2010 Dec 2.

PMID:
21130132
3.

The metabotropic glutamate receptor subtype 7 rs3792452 polymorphism is associated with the response to methylphenidate in children with attention-deficit/hyperactivity disorder.

Park S, Kim BN, Cho SC, Kim JW, Kim JI, Shin MS, Yoo HJ, Han DH, Cheong JH.

J Child Adolesc Psychopharmacol. 2014 May;24(4):223-7. doi: 10.1089/cap.2013.0079. Epub 2014 May 9.

PMID:
24815731
4.

Norepinephrine transporter gene (SLC6A2) is involved with methylphenidate response in Korean children with attention deficit hyperactivity disorder.

Song J, Song DH, Jhung K, Cheon KA.

Int Clin Psychopharmacol. 2011 Mar;26(2):107-13. doi: 10.1097/YIC.0b013e32834152d1.

PMID:
21127421
5.

Regional brain perfusion before and after treatment with methylphenidate may be associated with the G1287A polymorphism of the norepinephrine transporter gene in children with attention-deficit/hyperactivity disorder.

Park MH, Kim JW, Yang YH, Hong SB, Park S, Kang H, Kim BN, Shin MS, Yoo HJ, Cho SC.

Neurosci Lett. 2012 Apr 18;514(2):159-63. doi: 10.1016/j.neulet.2012.02.079. Epub 2012 Mar 3.

PMID:
22405810
6.

Norepinephrine genes predict response time variability and methylphenidate-induced changes in neuropsychological function in attention deficit hyperactivity disorder.

Kim BN, Kim JW, Cummins TD, Bellgrove MA, Hawi Z, Hong SB, Yang YH, Kim HJ, Shin MS, Cho SC, Kim JH, Son JW, Shin YM, Chung US, Han DH.

J Clin Psychopharmacol. 2013 Jun;33(3):356-62. doi: 10.1097/JCP.0b013e31828f9fc3.

PMID:
23609393
7.

Lack of association between response of OROS-methylphenidate and norepinephrine transporter (SLC6A2) polymorphism in Korean ADHD.

Lee SH, Kim SW, Lee MG, Yook KH, Greenhill LL, Fradin KN, Hong HJ.

Psychiatry Res. 2011 Apr 30;186(2-3):338-44. doi: 10.1016/j.psychres.2010.08.033. Epub 2010 Sep 21. Erratum in: Psychiatry Res. 2011 Jun 30;188(1):177. Frandin, Kelly N [corrected to Fradin, Kelly N].

PMID:
20863575
8.
9.

Methylphenidate side effect profile is influenced by genetic variation in the attention-deficit/hyperactivity disorder-associated CES1 gene.

Johnson KA, Barry E, Lambert D, Fitzgerald M, McNicholas F, Kirley A, Gill M, Bellgrove MA, Hawi Z.

J Child Adolesc Psychopharmacol. 2013 Dec;23(10):655-64. doi: 10.1089/cap.2013.0032.

PMID:
24350812
10.

Possible association of norepinephrine transporter -3081(A/T) polymorphism with methylphenidate response in attention deficit hyperactivity disorder.

Kim BN, Kim JW, Hong SB, Cho SC, Shin MS, Yoo HJ.

Behav Brain Funct. 2010 Oct 7;6:57. doi: 10.1186/1744-9081-6-57.

11.

Association of SNAP-25, SLC6A2, and LPHN3 with OROS methylphenidate treatment response in attention-deficit/hyperactivity disorder.

Song J, Kim SW, Hong HJ, Lee MG, Lee BW, Choi TK, Lee SH, Yook KH.

Clin Neuropharmacol. 2014 Sep-Oct;37(5):136-41. doi: 10.1097/WNF.0000000000000045.

PMID:
25229170
12.

Norepinephrine transporter -3081(A/T) and alpha-2A-adrenergic receptor MspI polymorphisms are associated with cardiovascular side effects of OROS-methylphenidate treatment.

Cho SC, Kim BN, Cummins TD, Kim JW, Bellgrove MA.

J Psychopharmacol. 2012 Mar;26(3):380-9. doi: 10.1177/0269881111405356. Epub 2011 May 31.

PMID:
21628343
13.

Genome-wide association study in German patients with attention deficit/hyperactivity disorder.

Hinney A, Scherag A, Jarick I, Albayrak Ö, Pütter C, Pechlivanis S, Dauvermann MR, Beck S, Weber H, Scherag S, Nguyen TT, Volckmar AL, Knoll N, Faraone SV, Neale BM, Franke B, Cichon S, Hoffmann P, Nöthen MM, Schreiber S, Jöckel KH, Wichmann HE, Freitag C, Lempp T, Meyer J, Gilsbach S, Herpertz-Dahlmann B, Sinzig J, Lehmkuhl G, Renner TJ, Warnke A, Romanos M, Lesch KP, Reif A, Schimmelmann BG, Hebebrand J; Psychiatric GWAS Consortium: ADHD subgroup.

Am J Med Genet B Neuropsychiatr Genet. 2011 Dec;156B(8):888-97. doi: 10.1002/ajmg.b.31246. Epub 2011 Oct 19.

PMID:
22012869
14.

Comprehensive phenotype/genotype analyses of the norepinephrine transporter gene (SLC6A2) in ADHD: relation to maternal smoking during pregnancy.

Thakur GA, Sengupta SM, Grizenko N, Choudhry Z, Joober R.

PLoS One. 2012;7(11):e49616. doi: 10.1371/journal.pone.0049616. Epub 2012 Nov 20.

15.

Possible effect of norepinephrine transporter polymorphisms on methylphenidate-induced changes in neuropsychological function in attention-deficit hyperactivity disorder.

Park S, Kim JW, Yang YH, Hong SB, Park MH, Kim BN, Shin MS, Yoo HJ, Cho SC.

Behav Brain Funct. 2012 May 16;8:22. doi: 10.1186/1744-9081-8-22.

16.

Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials.

Findling RL, Wigal SB, Bukstein OG, Boellner SW, Abikoff HB, Turnbow JM, Civil R.

Clin Ther. 2009 Aug;31(8):1844-55. doi: 10.1016/j.clinthera.2009.08.002.

PMID:
19808143
17.

Catechol-O-methyltransferase Val158Met polymorphism is associated with methylphenidate response in ADHD children.

Kereszturi E, Tarnok Z, Bognar E, Lakatos K, Farkas L, Gadoros J, Sasvari-Szekely M, Nemoda Z.

Am J Med Genet B Neuropsychiatr Genet. 2008 Dec 5;147B(8):1431-5. doi: 10.1002/ajmg.b.30704.

PMID:
18214865
18.

Pharmacogenetic predictors of methylphenidate dose-response in attention-deficit/hyperactivity disorder.

Froehlich TE, Epstein JN, Nick TG, Melguizo Castro MS, Stein MA, Brinkman WB, Graham AJ, Langberg JM, Kahn RS.

J Am Acad Child Adolesc Psychiatry. 2011 Nov;50(11):1129-1139.e2. doi: 10.1016/j.jaac.2011.08.002. Epub 2011 Sep 15.

19.

Genome-wide association scan of quantitative traits for attention deficit hyperactivity disorder identifies novel associations and confirms candidate gene associations.

Lasky-Su J, Neale BM, Franke B, Anney RJ, Zhou K, Maller JB, Vasquez AA, Chen W, Asherson P, Buitelaar J, Banaschewski T, Ebstein R, Gill M, Miranda A, Mulas F, Oades RD, Roeyers H, Rothenberger A, Sergeant J, Sonuga-Barke E, Steinhausen HC, Taylor E, Daly M, Laird N, Lange C, Faraone SV.

Am J Med Genet B Neuropsychiatr Genet. 2008 Dec 5;147B(8):1345-54. doi: 10.1002/ajmg.b.30867.

PMID:
18821565
20.

Association between the GRM7 rs3792452 polymorphism and attention deficit hyperacitiveity disorder in a Korean sample.

Park S, Jung SW, Kim BN, Cho SC, Shin MS, Kim JW, Yoo HJ, Cho DY, Chung US, Son JW, Kim HW.

Behav Brain Funct. 2013 Jan 7;9:1. doi: 10.1186/1744-9081-9-1.

Supplemental Content

Support Center